H omocystinuria is a rare autosomal recessive deficiency of CBS associated with an elevated blood tHcy concentration and a very high incidence of premature vascular disease. Moderately elevated tHcy also is believed to be a risk factor for CHD, atherothrombotic stroke, and peripheral vascular disease. A recent meta-analysis 1 estimated that each 5-mol/L tHcy increase is associated with a 60% (men) to 80% (women) greater risk of CHD. Although this evidence is compelling, only two 2,3 of five [2] [3] [4] [5] [6] published prospective studies have found tHcy concentration to be a CHD risk factor. One of these studies, 2 when extended by 2.5 years, no longer showed a statistically significant association between tHcy and CHD incidence, 7 nor did it subsequently find a relation between tHcy and risk of angina pectoris. 8 
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Heterozygous CBS deficiency, homozygosity for the thermolabile variant of MTHFR, and low dietary folate, vitamin B 12 , or vitamin B 6 (PLP) are among the factors that can elevate tHcy concentrations. 1 Prospective evidence relating these factors to incident CHD is limited. 7,9 -11 Two prospective epidemiological studies reported low dietary folate and B 6 11 or low serum folate 9 to be associated significantly with increased incidence of CHD. Another study 7 found low serum folate and vitamin B 6 associated, although not statistically significantly, with increased CHD incidence. This latter study also found the C 677 T mutation of the MTHFR gene was not associated with CHD incidence. 10 To provide additional prospective evidence on these topics, we used a nested case-cohort design within the ARIC study to determine the association of fasting serum tHcy with CHD incidence. In addition, we assessed the contributions to CHD of dietary and plasma B 12 , PLP, and folate, as well as several genetic variants associated with tHcy concentration.
Methods

Study Population
In 1987 through 1989, the ARIC study 12 recruited a population-based cohort of persons aged 45 to 64 years from 4 US communities. A total of 15 792 participants completed a home interview and clinic examination. ARIC reexamined participants in 1990 -1992 (93% return rate) and in 1993-1995 (86% return rate).
Baseline Measurements
We defined hypertension as systolic blood pressure Ն140 mm Hg or diastolic blood pressure Ն90 mm Hg or current use of antihypertensive medication. We expressed physical activity as a sport index ranging from 0 (low) to 5 (high). 13 Technicians measured waist (umbilical level) and hips (maximum) to compute waist/hip ratio. We computed body mass index (kg/m 2 ). Technicians measured average carotid intima-media thickness using standardized B-mode ultrasonography.
14, 15 We defined prevalent CHD at baseline, for exclusion, as a reported history of a physician-diagnosed heart attack, prior MI by ECG, prior cardiovascular surgery, or prior coronary angioplasty. ARIC also measured exertional angina by questionnaire 16 and prior stroke or transient ischemic attack through a standardized interview.
Trained interviewers collected information on usual alcohol intake and on dietary intake using an adaptation of Willett's food frequency questionnaire. 17 Interviewers asked about use of vitamin supplements in a medication interview. Because we did not obtain dose and frequency of vitamin supplementation, we coded vitamin supplement use as "any" versus "none" for analysis.
ARIC measured fasting plasma total cholesterol, 18 triglycerides, 19 HDL cholesterol, 20 and fibrinogen 21 and calculated LDL cholesterol. 22 We defined diabetes as fasting glucose Ն140 mg/dL, nonfasting glucose Ն200 mg/dL, or a physician diagnosis or pharmacological treatment for diabetes.
Ascertainment and Classification of Incident CHD Cases
ARIC ascertained all CHD events in the cohort. 12, 23 For the present study, we included CHD events occurring between ARIC visit 1 and December 31, 1991. The median follow-up time was 3.3 years (maximum of 5 years). We defined CHD incidence as (1) a definite or probable MI, (2) a silent MI between examinations by ECG, (3) a definite CHD death, or (4) a coronary revascularization.
Cohort Sample
We used a case-cohort design for the present study, in which information on plasma tHcy, B vitamins, and related genotypes was determined only for CHD cases and a stratified random sample of the ARIC cohort. For this reference cohort, we oversampled participants with thin average carotid intima-media thickness measurements at baseline (Ͻ30th percentile) and also stratified the sampling by age and sex.
Processing of Stored Baseline Samples
In 1995, after ARIC had identified the incident cases and cohort sample, technicians pulled these participants' baseline samples, frozen in [1987] [1988] [1989] . The technicians thawed the frozen buffy coat, extracted genomic DNA, 24 treated it with a proteinase K (1.9 g/50 to 500 ng DNA), placed the DNA in multiple aliquots, and froze them at -70°C. Approximately 90% of the sera for tHcy had been thawed once or twice previously, and 10% had never thawed. Previous evidence suggests tHcy is not altered with thawing and refreezing (M.R. Malinow, MD, unpublished data, 1997). The plasma aliquots for vitamin measurements had never been thawed.
Laboratory Measurements
The Oregon Regional Primate Research Center staff measured tHcy, in duplicate, as the sum of free and bound homocystine, homocysteine, and cysteine-homocysteine mixed disulfide using high-pressure liquid chromatography and electrochemical detection based on the method of Smolin and Schneider, 25 as previously described 26 with minor modifications. 27 The laboratory interspersed 3 quality-control samples with the study samples each day; these standards were 2 large, well-mixed pools obtained from American Red Cross plasma. The laboratory adjusted tHcy levels to the mean of the standard in each daily run to account for day-to-day method variability. The staff of the Oregon Regional Primate Research Center measured plasma folate and vitamin B 12 by the Quantiphase II Radioassay method supplied by Bio-Rad Diagnostics Group and PLP using a radioenzymatic assay supplied by Bühlmann Laboratories AG through American Laboratory Products Co. To assess laboratory reliability, ARIC included split-specimen, blinded duplicates prepared at the time of baseline blood drawing. This yielded the following Pearson coefficients: tHcy, rϭ0.95 (nϭ77); folate, rϭ0.97 (nϭ29); PLP, rϭ0.90 (nϭ29); and vitamin B 12 , rϭ0.91 (nϭ29).
We determined the presence or absence of the T 833 C and G 919 A mutations and the 68-bp insertion of the CBS gene. 28, 29 To determine the C 677 T mutation of the MTHFR gene, we used the method of Rozen and associates. 30 
Data Analysis
We excluded participants with prevalent CHD, stroke, or transient ischemic attack but not the 5% of participants whose angina status was positive or unknown by the Rose questionnaire, because the questionnaire's validity, especially in women, has been questioned. 31 We also excluded 6 participants with creatinine Ͼ2 mg/dL, 21 participants who had implausible values for energy intake, and 28 participants with missing tHcy values.
To determine the relation of tHcy with other variables, some of which may be confounders in this analysis, we categorized the cohort sample into fifths based on quintile cutpoints and used ANCOVA to compute age-, race-, and sex-adjusted mean levels or percentages of the other variables for each quintile. We also computed weighted correlations among pairs of vitamin variables or tHcy.
To test study hypotheses, we first used ANCOVA to compute age-, race-, and sex-adjusted geometric mean or percentage values of study variables for CHD cases versus the cohort after appropriate weighting for the stratified case-cohort sampling design. We used geometric means because tHcy and vitamin variables were right skewed.
We computed relative risks and 95% CIs of CHD in relation to categories of study variables using a weighted proportional hazards regression, accounting for the stratified random sampling and the case-cohort design by Barlow's method. 32 We tested for trend in relative risks across quintiles (coded 1 to 5) using a 2 test. We performed supplemental analyses using continuous instead of categorical independent variables. We initially used 2 sex-specific models, 1 of which was adjusted for age, race (black, white), and ARIC field center. In the final multivariate model, we adjusted for sex, age, race, field center, and the other factors related to CHD in this sample: smoking status (never, former, current), total cholesterol, HDL cholesterol, hypertension, and diabetes. In addition, we adjusted dietary vitamin intake for energy intake by including it as a continuous variable in the models.
Results
Sample Characteristics
The sample included 232 incident CHD cases (146 definite or probable MI, 19 silent MI, 30 definite fatal CHD, and 37 revascularization procedure) and a reference cohort sample of
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Correlates of tHcy
In the cohort sample, plasma folate, vitamin B 12 , and PLP all showed graded inverse associations across tHcy quintiles ( Waist/hip ratio, alcohol intake, and hypertension were weakly but positively associated with plasma tHcy concentration, but other CHD risk factors were not. We detected no homozygotes or heterozygotes for the G 919 A mutation of the CBS gene and only 3 heterozygotes for the T 833 C mutation (1 case, 2 noncases). There was no association between prevalence of the CBS insertion and tHcy ( Table 1 ). The prevalences of heterozygosity and homozygosity of the thermolabile MTHFR C677T mutation were 37% and 9%. MTHFR C677T homozygosity increased across each quintile of tHCy (Table 1) , and the association carried a P value for trend of 0.01.
Mean Differences Between CHD Cases and Noncases
Compared with the noncases, participants who subsequently developed CHD tended to have a higher baseline mean tHcy concentration; lower mean plasma concentrations of folate, 
Relative Risks of CHD
Initial modeling of CHD incidence suggested interactions (PՅ0.10) of sex with tHcy, plasma PLP, plasma folate, and vitamin supplement intake, so we used sex-specific models initially. As Table 3 illustrates, there was a positive association of tHcy with CHD incidence in women (P for trendϭ0.04), with an age-, race-, and center-adjusted relative risk of 2.53 for the highest quintile. There was no association in men. The relative risk of CHD for those in the upper 10th percentile of tHcy versus the lowest quintile was 3.48 (95% CIϭ0.96 to 12.6) in women but was 1.07 (95% CIϭ0.3 to 3.4) in men. There also were statistically significant age-, race-, and center-adjusted inverse associations of CHD with plasma PLP in both sexes and with plasma folate in women. Relative risks ranged from 0.36 to 0.48 for the fifth versus first quintile (Table 3 ). There was no significant association of CHD with dietary measures of B-vitamin intake (not shown). However, the age-, race-, and center-adjusted relative risk of CHD for vitamin supplement users versus nonusers was 0.47 (95% CIϭ0.22 to 0.97) in women but 1.02 (95% CIϭ0.6 to 1.9) in men. The C 677 T MTHFR mutation and the CBS insertion were not associated with CHD incidence. For example, adjusted for age, race, and center, the relative risks for heterozygosity and homozygosity for the C 677 T mutation of the MTHFR gene Although the simpler regression models suggested potential differences in associations by sex (Table 3) , interactions by sex were not significant (all PϾ0.09) after other risk factors were considered. This fact, plus the small number of events in women, led us to pool men and women for final modeling. As Table 4 shows, the multivariately adjusted association of CHD with plasma PLP was negative and statistically significant, with a relative risk for the highest versus lowest quintile of 0.28 (95% CIϭ0.1 to 0.7). Associations with CHD were positive for tHcy and negative for plasma folate and B 12 , although none of these was statistically significant. The multivariately adjusted relative risk of CHD for vitamin supplement use was 0.79 (95% CIϭ0.5 to 1.4). Reanalysis of Table 4 excluding the blacks did not change the conclusions.
Discussion
In this prospective study, we found fasting tHcy to be associated positively and relatively strongly at high levels with age-, race-, and center-adjusted incidence of CHD in women, although not in men. Yet, adjustment for other CHD risk factors abolished the association, suggesting that tHcy was not independently associated with CHD. In this same population, we previously observed a nonsignificant, positive cross-sectional association in both men and women between tHcy and carotid intima-media thickness. 33 Most other crosssectional case-control studies have shown an association between tHcy and CHD, 1, 34, 35 but they have not uniformly controlled for all confounding variables and are prone to survival bias. Furthermore, tHcy is often elevated after an acute coronary event. 36 Although cross-sectional studies have typically measured tHcy in cases at least 3 months after any acute CHD events, tHcy may have remained as a consequence of CHD.
In contrast with the cross-sectional studies, a majority of prospective epidemiological studies of subjects initially free of CHD, published either in full [2] [3] [4] [5] [6] [7] [8] or in abstract, 37, 38 do not show an association of tHcy and CHD incidence. This suggests that elevated tHcy may be a consequence, not a cause, of CHD. 6 Recent evidence suggests that endothelial dysfunction may raise plasma tHcy. 39 In patients with CHD, elevated tHcy strongly predicts a poor outcome, 40 further suggesting that it reflects the severity of CHD and possibly the risk of thrombosis.
Plasma PLP, B 12 , and folate, which are cofactors in homocysteine metabolism, were moderately strong correlates of tHcy, as has been documented previously. 1, 34, 35, [41] [42] [43] We found moderately strong inverse associations of CHD with plasma PLP, folate, and vitamin B 12 in women and with PLP in men. However, in multivariate analysis pooling men and women, only PLP remained independently associated with CHD. Previous evidence is not entirely consistent but suggests folate and PLP but not vitamin B 12 concentrations in the blood are associated negatively with CHD occurrence. 7, 9, 34, 35, [41] [42] [43] Only 2 of these previous studies 7,9 were prospective. Vitamin B 6 deficiency can cause atherosclerosis in animal models, and other possible mechanisms of how vitamin B 6 might protect against CHD have been hypothesized. 44 In contrast with a recent large study, 11 we found no significant association between questionnaire assessments of B vitamins from food and CHD incidence. On the other hand, we found that vitamin supplement use was associated with reduced risk of CHD in the age-, race-, and field centeradjusted model for women. Users of vitamin supplements had higher plasma B-vitamin concentrations than nonusers, sug- gesting that vitamin supplementation contributed to the inverse association between plasma PLP and CHD.
Despite the fact that MTHFR C677T homozygosity was associated with higher tHcy levels, we found no association of MTHFR C677T with CHD incidence. Most recent reports, 10, [45] [46] [47] but not all, 48 -50 have also found no association of MTHFR C677T with CHD. The T 833 C and G 919 A mutations of the CBS gene together account for Ն50% of the mutant alleles in patients with homocystinuria. 28, 51 Yet, heterozygosity for these 2 mutations in this population-based sample were too rare to be important determinants of elevated tHcy or of CHD risk. We also found no association of CHD with the CBS 68-bp insertion mutation, consistent with a previous report. 29 Our prospective findings add uncertainty to conclusions derived mostly from cross-sectional studies that tHcy is a major, independent, causative risk factor for CHD. Our findings point more strongly to the possibility that vitamin B 6 offers independent protection. Randomized trials, some of which are under way, are needed to better clarify the interrelationships of tHcy, B vitamins, and cardiovascular disease.
